Business Context and Reporting Period
Company: Entrada Therapeutics, Inc. (TRDA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Entrada is a clinical-stage biopharmaceutical company developing genetic medicines using its proprietary Endosomal Escape Vehicle (EEV) platform. The company focuses on neuromuscular diseases, specifically Duchenne muscular dystrophy (DMD), and inherited retinal diseases. It has no approved products and generates no product revenue.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Collaboration Revenue | $25.4 | $210.8 |
| Total Operating Expenses | $183.3 | $163.8 |
| Net Loss | $(143.8) | $65.6 (Income) |
| Cash, Cash Equivalents & Marketable Securities | $295.7 | $419.5 |
| Accumulated Deficit | $(273.1) | $(129.3) |
| Net Cash Used in Operating Activities | $(128.5) | $(41.6) |
Liquidity: As of December 31, 2025, the company held $295.7 million in cash, cash equivalents, and marketable securities. Management believes these resources are sufficient to fund operations into the third quarter of 2027.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $185.4 million (88%) to $25.4 million. This was primarily due to the substantial completion of research plan activities for the partnered candidate VX-670 in the first quarter of 2025, resulting in fewer reimbursable costs compared to 2024.
- Operating Loss: The company reported a net loss of $143.8 million in 2025, compared to net income of $65.6 million in 2024. The 2024 income was driven by a $75.0 million milestone payment from Vertex Pharmaceuticals for the clinical advancement of VX-670.
- Expense Increase: Total operating expenses increased by $19.5 million to $183.3 million. Research and Development (R&D) expenses rose by $17.0 million, driven by increased direct costs for DMD programs (ENTR-601-44 and ENTR-601-45) and higher unallocated personnel costs.
- Workforce Reduction: In April 2025, the company reduced its workforce by approximately 20% to refocus resources on clinical candidates, incurring $1.9 million in severance charges.
Guidance, Outlook, and Risks
Outlook and Milestones
- 2026 Clinical Plan: The company expects to progress clinical trials for ENTR-601-44 and ENTR-601-45 (DMD), file for an EU clinical trial for ENTR-601-50, and submit regulatory applications for ENTR-601-51.
- Data Readouts: Anticipates reporting data from two cohorts of ENTR-601-44 and one cohort of ENTR-601-45 during 2026.
- Vertex Partnership: Dosing completion for the partnered candidate VX-670 (Myotonic Dystrophy Type 1) is anticipated in mid-2026.
- Ocular Pipeline: Plans to announce a second clinical candidate for ocular diseases in the second half of 2026.
Key Risks and Contingencies
- Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require additional financing to sustain operations beyond late 2027. Failure to secure funding could force delays or termination of programs.
- Development Uncertainty: All therapeutic candidates are in preclinical or early clinical stages. There is no guarantee of regulatory approval or commercial success. The EEV platform is novel and unproven.
- Regulatory and Clinical Risks: Risks include delays in clinical trial enrollment, failure to demonstrate safety/efficacy, and potential clinical holds. The company previously experienced a clinical hold on ENTR-601-44 which was resolved in February 2025.
- Intellectual Property: Reliance on licensed IP from The Ohio State University and potential challenges to patent validity.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $295.7 million cash balance against the projected burn rate to confirm the Q3 2027 liquidity timeline.
- Vertex Agreement Status: Confirm the status of the "Amended Research Plan" with Vertex and the probability of future milestone payments, as revenue recognition is heavily dependent on this collaboration.
- Clinical Trial Progress: Monitor enrollment rates and safety data for the ELEVATE-44-201 and ELEVATE-45-201 trials, specifically the transition from Cohort 1 to Cohort 2 dosing.
- Regulatory Filings: Track the submission and acceptance of IND/CTA applications for ENTR-601-50 and ENTR-601-51 in 2026.
- Capital Markets: Assess the company's ability to raise additional capital given the "at-the-market" offering program established in November 2025 and current market conditions.